Speciality Medicines Denies Undisclosed Price-Sensitive Events

Company responds to BSE query on significant share price movement, confirming full regulatory compliance.
States no undisclosed material events or developments requiring disclosure under SEBI LODR Regulation 30.
Attributes price movement to market-driven factors and general investor sentiment.
Commits to continued monitoring and prompt disclosure of any future material events.